Ipca Laboratories Q1 FY27 earnings show margin expansion as export momentum strengthens

Investment View and Q1 FY27 Highlights

ICICI Direct Research retained its BUY view on Ipca Laboratories following a Q1 FY27 performance that was ahead of expectations across most parameters. The broker considers Ipca a steady pharmaceutical play, supported by its vertically integrated business model, strong domestic franchise, diversified export segments, available manufacturing capacity, and improving growth and margin trajectory.

Revenue increased 16.7 per cent quarter on quarter. Margin expansion was primarily driven by a better product mix and strong performance from Unichem.

Segment Performance

Domestic formulations revenue grew 13 per cent year on year to Rs 1,082 crore. Export formulations also reported broad-based growth, with branded exports increasing about 16 per cent to Rs 143.3 crore, generic exports rising 27 per cent to Rs 340 crore, and institutional exports growing 107 per cent to Rs 120 crore.

The API business grew 30 per cent year on year to Rs 423.7 crore. Subsidiaries, including Unichem, delivered about 19 per cent growth to Rs 669 crore.

Management Guidance and Growth Drivers

Management reiterated its 12 to 13 per cent FY27 growth guidance for the India business and raised consolidated FY27 revenue growth guidance to 14 to 16 per cent from 12 to 13 per cent earlier. FY27 EBITDA margin guidance was also raised to about 23 per cent from 22 per cent.

Management expects Ipca's base-business margin, excluding Unichem, to improve from 26 per cent to 30 per cent over the next two to three years, while consolidated margins could reach 25 to 26 per cent. The expected drivers include common API sourcing, use of Ipca's own API supplies, and leveraging Unichem's front end to sell combined portfolios in the US.

• Institutional-business growth is expected to be in the high-single digits in FY27, with institutional revenue of about Rs 260 crore to Rs 300 crore.
• Unichem revenue is expected to grow 10 per cent, with a 13 per cent EBITDA margin in FY27.
• Ipca and Unichem are expected to launch seven to eight products in the US.
• Ipca plans to add about 200 medical representatives to support a new division.
• Seven biosimilar products are in the pipeline, with biosimilar revenue expected from FY29 to FY30 as a large product loses patent protection.
• FY27 capex guidance is Rs 700 crore to Rs 800 crore. Additional manufacturing capacity is expected to be needed over the next two to three years for global-market expansion.

Financial Forecasts and Valuation

ICICI Direct expects Ipca's USFDA-focused plants, now out of the USFDA embargo, to support sustainable generic growth and more than 14 per cent growth in major export businesses.

The target price of Rs 2,190 is based on valuing Ipca at 18 times FY28E EBITDA of Rs 2,927 crore.

Key Risks

• A slower-than-expected ramp-up of new US launches.
• Recurring regulatory issues.